NVAX Relative Valuation
NVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVAX is overvalued; if below, it's undervalued.
Historical Valuation
Novavax Inc (NVAX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.25. The fair price of Novavax Inc (NVAX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：6.84
Fair
-8.69
PE
1Y
3Y
5Y
Trailing
Forward
10.69
EV/EBITDA
Novavax Inc. (NVAX) has a current EV/EBITDA of 10.69. The 5-year average EV/EBITDA is -12.44. The thresholds are as follows: Strongly Undervalued below -137.29, Undervalued between -137.29 and -74.87, Fairly Valued between 49.98 and -74.87, Overvalued between 49.98 and 112.41, and Strongly Overvalued above 112.41. The current Forward EV/EBITDA of 10.69 falls within the Historic Trend Line -Fairly Valued range.
8.09
EV/EBIT
Novavax Inc. (NVAX) has a current EV/EBIT of 8.09. The 5-year average EV/EBIT is 1.41. The thresholds are as follows: Strongly Undervalued below -30.15, Undervalued between -30.15 and -14.37, Fairly Valued between 17.19 and -14.37, Overvalued between 17.19 and 32.97, and Strongly Overvalued above 32.97. The current Forward EV/EBIT of 8.09 falls within the Historic Trend Line -Fairly Valued range.
2.01
PS
Novavax Inc. (NVAX) has a current PS of 2.01. The 5-year average PS is 2.62. The thresholds are as follows: Strongly Undervalued below -1.63, Undervalued between -1.63 and 0.50, Fairly Valued between 4.75 and 0.50, Overvalued between 4.75 and 6.87, and Strongly Overvalued above 6.87. The current Forward PS of 2.01 falls within the Historic Trend Line -Fairly Valued range.
-1.13
P/OCF
Novavax Inc. (NVAX) has a current P/OCF of -1.13. The 5-year average P/OCF is -15.56. The thresholds are as follows: Strongly Undervalued below -139.83, Undervalued between -139.83 and -77.69, Fairly Valued between 46.57 and -77.69, Overvalued between 46.57 and 108.70, and Strongly Overvalued above 108.70. The current Forward P/OCF of -1.13 falls within the Historic Trend Line -Fairly Valued range.
6.57
P/FCF
Novavax Inc. (NVAX) has a current P/FCF of 6.57. The 5-year average P/FCF is 24.41. The thresholds are as follows: Strongly Undervalued below -205.86, Undervalued between -205.86 and -90.73, Fairly Valued between 139.54 and -90.73, Overvalued between 139.54 and 254.68, and Strongly Overvalued above 254.68. The current Forward P/FCF of 6.57 falls within the Historic Trend Line -Fairly Valued range.
Novavax Inc (NVAX) has a current Price-to-Book (P/B) ratio of -7.09. Compared to its 3-year average P/B ratio of -0.32 , the current P/B ratio is approximately 2095.05% higher. Relative to its 5-year average P/B ratio of 6.67, the current P/B ratio is about -206.32% higher. Novavax Inc (NVAX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -58.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -37.80% , the current FCF yield is about -100.00% lower.
-7.11
P/B
Median3y
-0.32
Median5y
6.67
-34.52
FCF Yield
Median3y
-58.35
Median5y
-37.80
Competitors Valuation Multiple
The average P/S ratio for NVAX's competitors is 0.00, providing a benchmark for relative valuation. Novavax Inc Corp (NVAX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -16.64%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NVAX decreased by 14.68% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -143.53 to -287.29.
The secondary factor is the Revenue Growth, contributed -16.64%to the performance.
Overall, the performance of NVAX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Novavax Inc (NVAX) currently overvalued or undervalued?
What is Novavax Inc (NVAX) fair value?
How does NVAX's valuation metrics compare to the industry average?
What is the current P/B ratio for Novavax Inc (NVAX) as of Dec 05 2025?
What is the current FCF Yield for Novavax Inc (NVAX) as of Dec 05 2025?
What is the current Forward P/E ratio for Novavax Inc (NVAX) as of Dec 05 2025?